

Jerini AG Reports Financial Results for Fiscal Year 2008

Highlights:

- Jerini received European Marketing approval for Firazyr® (Icatibant) for the treatment of acute attacks of hereditary angioedema (HAE) in July 2008
- Jerini has launched Firazyr in Germany, Austria, Spain, Greece, Denmark, Luxemburg, and the UK
- Sales through named patient programs in France, Italy, Norway, and Belgium
- Further product launches are expected in Q2 in France, Italy, and Argentina
- Shire currently holds over 98 percent of Jerini's shares and provides support for the commercialization of Firazyr

Berlin, March 30, 2009 - Jerini AG (FSE:J14) announced today its financial results for the fiscal year ended December 31, 2008. Under International Financial Reporting Standards (IFRS), total revenues in 2008 decreased by 69 percent to EUR 4.4 million from EUR 14.2 million in 2007, primarily due to the termination of an agreement with Abbott resulting in a one-time payment in 2007. Sales from Firazyr in 2008 contributed EUR 0.4 million, while revenues from collaboration agreements amounted to EUR 4.0 million. "I am extremely pleased with the initial phase of the launch of Firazyr," said Theresa Heggie, CEO of Jerini. "Our collaboration with Shire has allowed us access to their extensive resources, enabling us to make Firazyr available in more countries faster than initially planned. Our highest priority is to make Firazyr available to patients suffering from HAE around the world as quickly as possible."

Research and development expenses decreased to EUR 17.8 million (compared to EUR 25.7 million in 2007). The loss from operations (EBIT) for 2008 was EUR 43.1 million (EUR 27.6 million in 2007) and net loss increased to EUR 47.5 million (EUR 29.1 million in 2007). Net cash burn (calculated as cash used in operating activities plus cash for investment in property and equipment) amounted to EUR 54.0 million in 2008 (EUR 27.5 million in 2007). As of December 31, 2008, cash and cash equivalents of continued and discontinued operations, including restricted cash for lease deposits of EUR 0.3 million in 2008 and 2007, amounted to EUR 6.8 million (compared to EUR 38.2 million in 2007)

Outlook

Jerini, with the support of its main shareholder Shire, is focusing on establishing efficient sales and distribution structures for Firazyr's product launches around the world. Firazyr has now been launched in Germany, Austria, Spain, Greece, Denmark, and the UK, and is available through named patient sale programs in France, Italy, Norway and Belgium. Feedback from patients and physicians continues to be very positive. Additional product launches in France, Italy, and Argentina are planned for the second quarter of 2009.

Jerini remains committed to making Firazyr available to patients suffering from HAE in as many countries as possible and is pursuing regulatory approval in the US and other countries. Marketing Authorization Applications were submitted in Argentina, Brazil, Mexico, Switzerland, and Russia in the fourth quarter of 2008, potentially giving patients in these countries access to Firazyr beginning in the second half of 2009 and in early 2010. Additional submissions are planned in the second quarter of 2009 in Canada and Australia.

Following Jerini's meeting and discussions with the US Food and Drug Administration (FDA) in December 2008, plans are underway to initiate a placebo-controlled confirmatory Phase III trial in the third quarter of 2009. After this trial has been completed, Jerini will submit a complete response to the FDA's "Not Approvable" letter received in April 2008.

Jerini continues to explore options to divest the company's non-strategic assets not related to Firazyr, including Jerini Ophthalmic, Inc., JPT Peptide Technologies GmbH, and the preclinical programs.

About Jerini AG

Jerini is a pharmaceutical company based in Berlin, Germany. On July 3, 2008, Jerini and Shire Limited's German wholly-owned indirect subsidiary Shire Deutschland Investments GmbH ("Shire") entered into a business combination agreement regarding a strategic partnership. Jerini is now a subsidiary of Shire plc and a member of the Shire group of companies. Shire currently holds more than 98 percent of Jerini's shares and has requested that a resolution be passed at Jerini's 2009 General Shareholders' Meeting calling for the transfer of the remaining shares held by Jerini's minority shareholders.

ISIN: DE0006787476

For questions, please contact:

Stacy Wiedenmann
Director Investor Relations &
Corporate Communications
Jerini AG
Invalidenstr. 130
10115 Berlin
T + 49 - 30 - 97893 - 285
X + 49 - 30 - 97893 - 105
wiedenmann@jerini.com